{"id":"semaglutide-b","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Vomiting"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Abdominal pain"}]},"_chembl":{"chemblId":"CHEMBL4752331","moleculeType":"Unknown","molecularWeight":"4113.64"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Semaglutide B works by binding to the GLP-1 receptor in the pancreas, stimulating insulin secretion and inhibiting glucagon release, which helps to lower blood glucose levels. This mechanism also leads to weight loss and improved cardiovascular risk factors.","oneSentence":"Semaglutide B is a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics the action of the natural hormone GLP-1 to regulate blood sugar levels.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:33:51.649Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT07207148","phase":"","title":"People With Multiple Sclerosis Treated With Ocrelizumab and GLP-1 Agonists","status":"RECRUITING","sponsor":"Northwestern University","startDate":"2025-11-15","conditions":"Multiple Sclerosis","enrollment":100},{"nctId":"NCT06409130","phase":"PHASE2","title":"Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2024-05-20","conditions":"Alcohol-related Liver Disease","enrollment":270},{"nctId":"NCT06717698","phase":"PHASE2","title":"A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease","status":"RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2024-12-02","conditions":"Chronic Kidney Disease","enrollment":465},{"nctId":"NCT07285902","phase":"PHASE3","title":"A Study Comparing the Efficacy and Safety of HRS9531 Injection With Semaglutide Injection in Subjects With Obesity","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fujian Shengdi Pharmaceutical Co., Ltd.","startDate":"2025-12-25","conditions":"Obesity","enrollment":572},{"nctId":"NCT07357766","phase":"PHASE3","title":"A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body Weight","status":"NOT_YET_RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2026-06-22","conditions":"Overweight, Obesity","enrollment":1400},{"nctId":"NCT07357740","phase":"PHASE2","title":"A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 Diabetes","status":"NOT_YET_RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2026-08-27","conditions":"Diabetes Mellitus, Type 2","enrollment":400},{"nctId":"NCT07282613","phase":"PHASE3","title":"A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes","status":"NOT_YET_RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2026-08-04","conditions":"Diabetes Mellitus, Type 2","enrollment":80},{"nctId":"NCT07081178","phase":"","title":"A Non-interventional Study Investigating Semaglutide in Combination With Lifestyle-based Modifications for the Management of Obesity in Real-World Clinical Practice in Germany (WeGo Real Germany).","status":"ENROLLING_BY_INVITATION","sponsor":"Novo Nordisk A/S","startDate":"2025-08-08","conditions":"Obesity","enrollment":555},{"nctId":"NCT06852391","phase":"PHASE4","title":"JOULE - Metabolic Adaptation to Weight Loss in Response to a Behavioural Lifestyle Program With or Without Semaglutide in Adolescents With Obesity","status":"RECRUITING","sponsor":"McMaster University","startDate":"2025-06-18","conditions":"Obesity (Disorder)","enrollment":74},{"nctId":"NCT06267092","phase":"PHASE1","title":"A Study of How CagriSema Works on Appetite in People With Excess Body Weight","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2024-02-15","conditions":"Overweight, Obesity","enrollment":164},{"nctId":"NCT06299098","phase":"PHASE2","title":"A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass Preservation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2024-03-13","conditions":"Obesity","enrollment":1005},{"nctId":"NCT04940078","phase":"PHASE1","title":"A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Combined Versus Separate Injections in People With Overweight or Obesity","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2021-07-07","conditions":"Obesity & Overweight","enrollment":40},{"nctId":"NCT07011667","phase":"PHASE3","title":"A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2025-06-03","conditions":"Obesity","enrollment":609},{"nctId":"NCT05478252","phase":"PHASE3","title":"A Research Study to Compare Two Semaglutide Medicines in People With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2022-08-03","conditions":"Diabetes Mellitus, Type 2","enrollment":388},{"nctId":"NCT06797869","phase":"PHASE2","title":"A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2025-01-29","conditions":"Diabetes Mellitus, Type 2, Diabetic Peripheral Neuropathy","enrollment":142},{"nctId":"NCT05784402","phase":"PHASE1","title":"A Research Study to Compare How Much Semaglutide is Found in the Blood With Different Tablets of Oral Semaglutide in Healthy Participants","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2023-03-16","conditions":"Healthy Participants","enrollment":264},{"nctId":"NCT06410352","phase":"PHASE4","title":"Effectiveness of Weight Loss Methods on Lifespan for Metabolic Syndrome","status":"RECRUITING","sponsor":"University Medical Center, Kazakhstan","startDate":"2024-03-01","conditions":"Metabolic Syndrome","enrollment":220},{"nctId":"NCT06642584","phase":"PHASE1","title":"A Research Study Looking at New Protein-based Tablets in Healthy Men - Oral Formulation IV","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2024-10-15","conditions":"Healthy Volunteers Type 2 Diabetes","enrollment":90},{"nctId":"NCT07184086","phase":"PHASE1","title":"A Study to See How Metabolism is Influenced by Weight Loss Due to Intervention With Cagrilintide and Semaglutide Compared to Diet","status":"RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2025-09-26","conditions":"Obesity","enrollment":80},{"nctId":"NCT03884075","phase":"PHASE2","title":"Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)","status":"RECRUITING","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2019-07-24","conditions":"Non-Alcoholic Steatohepatitis, Non-Alcoholic Fatty Liver Disease","enrollment":84},{"nctId":"NCT07179120","phase":"PHASE2","title":"Can Fat-Burning Shots Boost Fertility? Comparing Weight-Loss Injections vs. Healthy Habits for Obese Men With Low Sperm Health","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital of Wenzhou Medical University","startDate":"2026-05-01","conditions":"Obesity-related Male Infertility","enrollment":180},{"nctId":"NCT04126603","phase":"PHASE4","title":"Impact of Semaglutide on CD34+ EPC and Fat Derived MSC","status":"COMPLETED","sponsor":"Sabyasachi Sen","startDate":"2019-08-01","conditions":"Diabetes Mellitus, Type 2","enrollment":10},{"nctId":"NCT06716307","phase":"PHASE1","title":"A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Single Doses of Different Versions of Injectable CagriSema in Adults With Overweight or Obesity","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2024-12-02","conditions":"Obesity","enrollment":18},{"nctId":"NCT07087795","phase":"PHASE1","title":"A Study to See the Effect of NNC0194-0499 Alone or in Combination With Semaglutide on Blood Sugar Control in People Living With Type 1 Diabetes","status":"RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2025-07-01","conditions":"Diabetes Mellitus, Type 1","enrollment":96},{"nctId":"NCT06649344","phase":"PHASE3","title":"A Study of HRS9531 Versus Semaglutide Once Weekly as Add-on Therapy to Metformin Monotherapy or in Combination With SGLT2 Inhibitors in Participants With Type 2 Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fujian Shengdi Pharmaceutical Co., Ltd.","startDate":"2024-10-31","conditions":"Type 2 Diabetes","enrollment":884},{"nctId":"NCT06946628","phase":"PHASE3","title":"New Triple Therapy in Newly Diagnosed Type 2 Diabetes","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-06-01","conditions":"Diabetes Mellitus","enrollment":296},{"nctId":"NCT06821919","phase":"","title":"Impact of Antiglycemic & Immunosuppressive Therapies on NETosis in Diabetes & Kidney Disease (NETs - Neutrophil Traps)","status":"RECRUITING","sponsor":"Western Galilee Hospital-Nahariya","startDate":"2024-05-13","conditions":"Diabetes Mellitus, Kidney Disease","enrollment":70},{"nctId":"NCT03789578","phase":"PHASE1","title":"A Research Study to Look at How Insulin 287 and Semaglutide Work in the Body of People With Type 2 Diabetes When Taken Alone or Together","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2019-01-17","conditions":"Diabetes Mellitus, Type 2","enrollment":30},{"nctId":"NCT05689099","phase":"PHASE1","title":"A Research Trial Looking at the Comparability of 2 Different Concentrations of Semaglutide for the 0.5 Milligram (mg) Dose","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2023-01-17","conditions":"Diabetes Mellitus, Type 2, Healthy Participants","enrollment":20},{"nctId":"NCT05429593","phase":"PHASE1","title":"A Research Study Investigating How Semaglutide and Dapagliflozin Act in Your Body When Dosed in One Tablet","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2022-06-22","conditions":"Healthy Volunteers","enrollment":152},{"nctId":"NCT05129891","phase":"PHASE1","title":"A Research Study Looking at New Protein-based Tablets in Healthy Male Participants","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2021-11-03","conditions":"Healthy Volunteers, High Blood Cholesterol Levels, Type 2 Diabetes","enrollment":384},{"nctId":"NCT05766709","phase":"PHASE1","title":"A Research Study Comparing Blood Levels of Medicines NNC0194-0499 and Semaglutide Administered as a Combination Formulation Versus Two Separate Formulations","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2023-03-02","conditions":"Non-alcoholic Steatohepatitis","enrollment":53},{"nctId":"NCT06243536","phase":"PHASE4","title":"The Effect of Semaglutide on Disordered Eating Behaviour in Type 2 Diabetic Patients","status":"UNKNOWN","sponsor":"University Hospital Sestre Milosrdnice","startDate":"2024-02-01","conditions":"Type 2 Diabetes, Overweight, Disordered Eating Behaviors","enrollment":60},{"nctId":"NCT05232708","phase":"PHASE1","title":"A Clinical Trial Looking at the Comparability of 2 Different Forms of Semaglutide","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2022-01-19","conditions":"Healthy Volunteers (Diabetes Mellitus, Type 2)","enrollment":18},{"nctId":"NCT05586802","phase":"PHASE3","title":"Sex Steroids Balance for Metabolic and Reproductive Health in Klinefelter Syndrome","status":"RECRUITING","sponsor":"Georgios Papadakis","startDate":"2023-03-21","conditions":"Klinefelter Syndrome","enrollment":150},{"nctId":"NCT04524832","phase":"PHASE1","title":"Research Study Comparing New Tablets of Semaglutide in New Doses, in Healthy People","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2020-09-29","conditions":"Diabetes Mellitus, Type 2","enrollment":290},{"nctId":"NCT05046873","phase":"PHASE1","title":"A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2021-09-06","conditions":"Diabetes Mellitus, Type 2","enrollment":16},{"nctId":"NCT04513704","phase":"PHASE1","title":"A Clinical Trial Comparing Semaglutide in Healthy People Who Eat and Take the Medicine at Different Times","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2020-08-28","conditions":"Healthy Volunteers Type 2 Diabetes","enrollment":156},{"nctId":"NCT04187300","phase":"PHASE1","title":"A Research Study Looking at the Comparability (Bioequivalence) of Two Forms of Semaglutide in Two Different Pen-injectors in People With Overweight or Obesity","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2019-12-16","conditions":"Overweight, Obesity","enrollment":68},{"nctId":"NCT04143945","phase":"PHASE2","title":"A Study Comparing the Injection Site Pain Experience After the Injection of Semaglutide B and Semaglutide D With 2 Different Injection Pens, a Compound for the Treatment of Type 2 Diabetes and Obesity","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2019-10-28","conditions":"Healthy Volunteers Diabetes Mellitus, Type 2, Healthy Volunteers Overweight, Healthy Volunteers Obesity","enrollment":104},{"nctId":"NCT03638778","phase":"PHASE1","title":"Research Study Comparing Different Tablets With the Study Medicine Semaglutide in Healthy Men","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2018-08-17","conditions":"Diabetes Mellitus, Type 2","enrollment":105},{"nctId":"NCT00696657","phase":"PHASE2","title":"A Randomised Controlled Clinical Trial in Type 2 Diabetes Comparing Semaglutide to Placebo and Liraglutide","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2008-06-03","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":415},{"nctId":"NCT00851773","phase":"PHASE1","title":"Safety, Tolerability, and Profile of Action of Drug in the Body of NN9535 in Healthy Male Japanese and Caucasian Subjects","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2009-02","conditions":"Diabetes, Healthy","enrollment":84},{"nctId":"NCT00813020","phase":"PHASE1","title":"A Clinical Trial Investigating the Comparison of Three Different Concentrations of NN9535 in Healthy Male Subjects","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2009-01","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":44},{"nctId":"NCT01766245","phase":"PHASE1","title":"A Randomised, Single Centre, Double-blind, Two-period, Cross-over Trial in Healthy Subjects Investigating the Bioequivalence Between Subcutaneous Injections of Semaglutide Produced by Two Manufacturing Processes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2012-12","conditions":"Diabetes, Healthy","enrollment":28},{"nctId":"NCT01866748","phase":"PHASE1","title":"Investigation on Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses of a Long-acting GLP-1 Analogue (Semaglutide) in an Oral Formulation in Healthy Male Subjects","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2013-05","conditions":"Diabetes, Diabetes Mellitus, Type 2, Healthy","enrollment":170}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Semaglutide B","genericName":"Semaglutide B","companyName":"Novo Nordisk A/S","companyId":"novo-nordisk","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Semaglutide is a medication being studied for conditions such as non-alcoholic Steatohepatitis, type 2 diabetes, and obesity, as part of a combination formulation with NNC0194-0499. The exact mechanism of action of semaglutide is unknown.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}